S10 - Making the Move to Mealtime Insulin in Type 2 Diabetes: A Patient-Centered Approach

Saturday, August 13, 2022

10:15 AM – 11:15 AM ET

Location: Ballroom I

CE/CME Hours: 1.00

CE/CME Hours: 1.00
Pharmacology Hours: 1.00
Social Work CE Hours: 1.00
Activity Type: Application-Based
UAN: JA4008258-0000-22-264-L01-P
CHES/MCHES: 1.00

The CARES Initiative

This educational program focuses on the latest data on mealtime insulin in patients with type 2 diabetes mellitus. In this program, clinicians will incorporate appropriate treatment intensification strategies in consideration of patient-related factors, the latest clinical data, and key parameters for monitoring clinical response to mealtime insulin. Through this program, clinicians will improve their level of comfort with initiating mealtime insulins to optimize glycemic outcomes, including in underserved populations. Innovative learning strategies will reinforce the latest best practices to support clinician and patient understanding of the latest strategies in glycemic management.

This education was created in partnership with Med Learning Group

Commercial Support: This education is supported by an educational grant from Eli Lilly and Company

Invited Presenter(s)

Kathleen Dungan, MD, MPH

Endocrinologist/Professor
The Ohio State University
Columbus, Ohio

Disclosure: Abbott (Individual(s) Involved: Self; Products/Services: Diabetes): Other Research Support; Dexcom (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant, Other Research Support; Eli Lilly (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant; Elsevier (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant; Novo Nordisk (Individual(s) Involved: Self; Products/Services: diabetes): Other Research Support; Sanofi (Individual(s) Involved: Self; Products/Services: Diabetes): Other Research Support; Viacyte (Individual(s) Involved: Self; Products/Services: Diabetes): Other Research Support

PDF
Javier Morales, MD, FACP, FACE

Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Disclosure: Amgen (Individual(s) Involved: Self; Products/Services: Diabetes): Speaker/Honoraria; Bayer (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant, Speaker/Honoraria; Boehringer Ingleheim (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant, Speaker/Honoraria; Eli Lilly and Company (Individual(s) Involved: Self; Products/Services: Diabetes): Consultant, Speaker/Honoraria; Novo Nordisk Inc. (Individual(s) Involved: Self; Products/Services: diabetes): Consultant, Speaker/Honoraria; Zealand Pharmaceuticals (Individual(s) Involved: Self; Products/Services: Diabetes): Speaker/Honoraria